Abstract
Background: Alzheimer’s disease (AD) is the most common neurodegenerative disorder, neuropathologically characterized by aggregates of β-amyloid peptides, which deposit as senile plaques, and of TAU protein, which forms neurofibrillary tangles. It is now widely accepted that neuroinflammation is implicated in AD pathogenesis.
Method: Indeed, inflammatory mediators, such as cytokines and chemokines (chemotactic cytokines) can impact on the Alzheimer´s amyloid precursor protein by affecting its expression levels and amyloidogenic processing and/or β -amyloid aggregation. Additionally, cytokines and chemokines can influence kinases’ activities, leading to abnormal TAU phosphorylation. To date there is no cure for AD, but several therapeutic strategies have been directed to prevent neuroinflammation. Anti-inflammatory, but also anti-amyloidogenic compounds, such as flavonoids were shown to favourably modulate some pathological events associated with neurodegeneration. Conclusion: This review focuses on the role of cytokines and chemokines in AD-associated pathologies, and summarizes the potential anti-inflammatory therapeutic approaches aimed at preventing or slowing down disease progression.Keywords: Neuroinflammation, cytokines, chemokines, amyloid precursor protein, β-amyloid, TAU.
Current Alzheimer Research
Title:Impact of Cytokines and Chemokines on Alzheimer’s Disease Neuropathological Hallmarks
Volume: 14 Issue: 8
Author(s): Catarina Domingues, Odete A.B. da Cruz e Silva and Ana Gabriela Henriques*
Affiliation:
- Neurosciences and Signalling Laboratory, Department of Medical Sciences and Institute of Biomedicine - iBiMED, University of Aveiro, P.O. Box: 3810-193, Aveiro,Portugal
Keywords: Neuroinflammation, cytokines, chemokines, amyloid precursor protein, β-amyloid, TAU.
Abstract: Background: Alzheimer’s disease (AD) is the most common neurodegenerative disorder, neuropathologically characterized by aggregates of β-amyloid peptides, which deposit as senile plaques, and of TAU protein, which forms neurofibrillary tangles. It is now widely accepted that neuroinflammation is implicated in AD pathogenesis.
Method: Indeed, inflammatory mediators, such as cytokines and chemokines (chemotactic cytokines) can impact on the Alzheimer´s amyloid precursor protein by affecting its expression levels and amyloidogenic processing and/or β -amyloid aggregation. Additionally, cytokines and chemokines can influence kinases’ activities, leading to abnormal TAU phosphorylation. To date there is no cure for AD, but several therapeutic strategies have been directed to prevent neuroinflammation. Anti-inflammatory, but also anti-amyloidogenic compounds, such as flavonoids were shown to favourably modulate some pathological events associated with neurodegeneration. Conclusion: This review focuses on the role of cytokines and chemokines in AD-associated pathologies, and summarizes the potential anti-inflammatory therapeutic approaches aimed at preventing or slowing down disease progression.Export Options
About this article
Cite this article as:
Domingues Catarina, da Cruz e Silva A.B. Odete and Henriques Gabriela Ana*, Impact of Cytokines and Chemokines on Alzheimer’s Disease Neuropathological Hallmarks, Current Alzheimer Research 2017; 14 (8) . https://dx.doi.org/10.2174/1567205014666170317113606
DOI https://dx.doi.org/10.2174/1567205014666170317113606 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Therapeutic Value of Natural Agents to Treat miRNA Targeted Breast Cancer in African-American and Caucasian-American Women
Current Drug Targets Targeting Schistosome Histone Modifying Enzymes for Drug Development
Current Pharmaceutical Design Overview of Brain Tumor Stem Cells – Implications for Treatment
Current Signal Transduction Therapy Polyphenols as Potential Inhibitors of Amyloid Aggregation and Toxicity:Possible Significance to Alzheimers Disease
Mini-Reviews in Medicinal Chemistry CNS Immune Surveillance and Neuroinflammation: Endocannabinoids Keep Control
Current Pharmaceutical Design Potassium Channels: Novel Emerging Biomarkers and Targets for Therapy in Cancer
Recent Patents on Anti-Cancer Drug Discovery The Forkhead Transcription Factor FOXO3a Controls Microglial Inflammatory Activation and Eventual Apoptotic Injury through Caspase 3
Current Neurovascular Research Predicting Hub Genes of Glioblastomas Based on a Support Vector Machine Combined with CFS Algorithms
Current Bioinformatics New Promises to Cure Cancer and Other Genetic Diseases/Disorders: Epi-drugs Through Epigenetics
Current Topics in Medicinal Chemistry Islet-Brain (IB)/JNK-Interacting Proteins (JIPs): Future Targets for the Treatment of Neurodegenerative Diseases?
Current Neurovascular Research Estrogen Receptor Signaling: Impact on Cell Functions
Current Signal Transduction Therapy Pisosterol Induces G2/M Cell Cycle Arrest and Apoptosis via the ATM/ATR Signaling Pathway in Human Glioma Cells
Anti-Cancer Agents in Medicinal Chemistry Macrocyclic Proteasome Inhibitors
Current Medicinal Chemistry Natural Molecules as Talented Inhibitors of Nucleotide Pyrophosphatases/ Phosphodiesterases (PDEs)
Current Topics in Medicinal Chemistry Pathophysiology of Blood-Spinal Cord Barrier in Traumatic Injury and Repair
Current Pharmaceutical Design Inhibitors of Catechol-O-Methyltransferase
CNS & Neurological Disorders - Drug Targets The Role of Mitochondria in Brain Aging and the Effects of Melatonin
Current Neuropharmacology Xanthohumol: A Metabolite with Promising Anti-Neoplastic Potential
Anti-Cancer Agents in Medicinal Chemistry Multiple Roles for Glycogen Synthase Kinase-3 as a Drug Target in Alzheimers Disease
Current Drug Targets Structural Polymorphism of Amyloid Oligomers and Fibrils Underlies Different Fibrillization Pathways: Immunogenicity and Cytotoxicity
Current Protein & Peptide Science